P05-13. Fragments of HIV-1 gp41 derivatives presented on virus-like particles with preserved binding affinity for broadly neutralizing antibodies
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1742-4690
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
P05-13. Fragments of HIV-1 gp41 derivatives presented on virus-like particles with preserved binding affinity for broadly neutralizing antibodies ; volume:6 ; number:3 ; day:22 ; month:10 ; year:2009 ; pages:1 ; date:10.2009
Retrovirology ; 6, Heft 3 (22.10.2009), 1, 10.2009
- Creator
-
Benen, T.
- Contributor
-
Kliche, A.
Wagner, R.
SpringerLink (Online service)
- DOI
-
10.1186/1742-4690-6-S3-P89
- URN
-
urn:nbn:de:1111-201608078123
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Benen, T.
- Kliche, A.
- Wagner, R.
- SpringerLink (Online service)
Other Objects (12)
Broadly Neutralizing Antibodies for HIV Eradication
P19-11. Generation of virus-like particles expressing different HIV-1 glycoproteins for induction of broadly neutralizing antibodies
The expanding array of HIV broadly neutralizing antibodies
Autoreactivity profiles of influenza hemagglutinin broadly neutralizing antibodies
Sequential immunizations with a panel of HIV-1 Env virus-like particles coach immune system to make broadly neutralizing antibodies
Design clues from functional constraints and broadly neutralizing antibodies
Vaccination induces broadly neutralizing antibody precursors to HIV gp41
An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models
Identification and characterization of broadly neutralizing antibodies targeting viral infections
Ultrapotent Broadly Neutralizing Human‐llama Bispecific Antibodies against HIV‐1
Broadly neutralizing antibodies and vaccine design against HIV-1 infection
HIV-1 cell-to-cell transmission and broadly neutralizing antibodies
Broadly Neutralizing Antibodies for HIV Eradication
P19-11. Generation of virus-like particles expressing different HIV-1 glycoproteins for induction of broadly neutralizing antibodies
The expanding array of HIV broadly neutralizing antibodies
Autoreactivity profiles of influenza hemagglutinin broadly neutralizing antibodies
Sequential immunizations with a panel of HIV-1 Env virus-like particles coach immune system to make broadly neutralizing antibodies
Design clues from functional constraints and broadly neutralizing antibodies
Vaccination induces broadly neutralizing antibody precursors to HIV gp41
An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models
Identification and characterization of broadly neutralizing antibodies targeting viral infections
Ultrapotent Broadly Neutralizing Human‐llama Bispecific Antibodies against HIV‐1
Broadly neutralizing antibodies and vaccine design against HIV-1 infection
HIV-1 cell-to-cell transmission and broadly neutralizing antibodies
Broadly Neutralizing Antibodies for HIV Eradication
P19-11. Generation of virus-like particles expressing different HIV-1 glycoproteins for induction of broadly neutralizing antibodies
The expanding array of HIV broadly neutralizing antibodies
Autoreactivity profiles of influenza hemagglutinin broadly neutralizing antibodies
Sequential immunizations with a panel of HIV-1 Env virus-like particles coach immune system to make broadly neutralizing antibodies
Design clues from functional constraints and broadly neutralizing antibodies
Vaccination induces broadly neutralizing antibody precursors to HIV gp41
An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models
Identification and characterization of broadly neutralizing antibodies targeting viral infections
Ultrapotent Broadly Neutralizing Human‐llama Bispecific Antibodies against HIV‐1
Broadly neutralizing antibodies and vaccine design against HIV-1 infection